Cargando…
Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma
The cell surface receptor CD70 has been previously reported as a promising target for B-cell lymphomas and several solid cancers including renal cell carcinoma. We describe herein the characterization and efficacy of a novel CD70 targeted thorium-227 conjugate (CD70-TTC) comprising the combination o...
Autores principales: | Hagemann, Urs B., Mihaylova, Dessislava, Uran, Steinar R., Borrebaek, Joergen, Grant, Derek, Bjerke, Roger M., Karlsson, Jenny, Cuthbertson, Alan S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593563/ https://www.ncbi.nlm.nih.gov/pubmed/28915592 http://dx.doi.org/10.18632/oncotarget.16910 |
Ejemplares similares
-
Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model
por: Karlsson, Jenny, et al.
Publicado: (2023) -
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy
por: Hagemann, Urs B., et al.
Publicado: (2020) -
Targeted thorium-227 conjugates as treatment options in oncology
por: Karlsson, Jenny, et al.
Publicado: (2023) -
Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model
por: Wickstroem, Katrine, et al.
Publicado: (2019) -
Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
por: Lejeune, Pascale, et al.
Publicado: (2021)